ClinicalTrials.gg
Active, not recruitingNCT05540782Updated Oct 14, 2026

A Study of Cognitive Health in Survivors of Prostate Cancer

An observational study in Prostate Cancer and Survivorship, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 7 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Updated Oct 14, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
200
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center — 15 open to participants now, 41 under way, 4 of them phase 3. Prostatic Neoplasms · Memorial Sloan Kettering Cancer Center.

Enrollment
13th of 24
200 · median 201
Started
2022
with 2 others
Observational
24 of 138
1 open now
Primary completion
2027-09
later than 23 of 40 live
Registered
123rd of 138
by date

Among the 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 13th largest by enrollment of the 24 observational ones that give a count, is one of 3 that started in 2022, is one of 24 observational ones, reaches primary completion later than 23 of the 40 other live ones, and was the 123rd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 2 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Prostatic Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to collect information that may help the researchers understand the relationship between prostate cancer survivors' experiences of cancer-related cognitive dysfunction (CRCD) and their other conditions (co-morbid factors), including anxiety, depression, and insomnia. The researchers will also find out how additional things may contribute to CRCD, including social factors, the characteristics of participants' prostate cancer, and the type of cancer treatment or other medications they received.

03

Conditions studied

  • Prostate Cancer
  • Survivorship

Browse trials for

Keywords

  • Cognitive health
  • Quality of Life
  • 22-223
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Sampling method
Non-probability sample

Study population

Patients from Memorial Sloan Kettering Cancer Center (MSK) and the Ralph Lauren Center (RLC), an MSK-affiliated Harlem community clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English-speaking
  • Age 18 years or older
  • History of documented PC of any stage
  • No evidence of PC Disease

Exclusion criteria

Exclusion Criteria:

  • \<1 month since completion of surgery, radiation, chemotherapy, or ADT
  • Diagnosis of Alzheimer's disease, vascular dementia, Parkinson disease, or other organic brain disorder
  • Score >10 indicative of dementia on Blessed Orientation Memory Concentration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
200 participants (actual)
Patient registry
No

Groups and cohorts

  • Survivors of Prostate Cancer

    This is a cross-sectional study with a one-time data collection process and no subsequent follow-ups. If patients did not opt out of receiving study-specific text communications, they may also receive text messages with reminders about surveys and/or direct links to REDCap to complete the surveys. Text-based communications will be delivered using the secure, HIPAA-compliant Mosio texting platform developed for clinical research.

    Behavioral: PROMIS-SF v2.0 -Cognitive Function 8a

Interventions

  • BehavioralPROMIS-SF v2.0 -Cognitive Function 8a

    Patient-Reported Outcomes (PROs)

06

What researchers measure

Primary outcomes

  1. number of participants with co-morbid symptoms

    All participants will be evaluable as long as they have completed the PROMIS-SF v2.0 - Cognitive Function 8a.

    Time frame: 1 year

07

Study locations

7 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2022 (actual). Primary completion is estimated for Sep 2027, 60 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2022
First posted
Sep 15, 2022
StartActual
Sep 8, 2022
Primary completionEst.
Sep 8, 2027was Sep 2026
CompletionEst.
Sep 8, 2027was Sep 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 8, 2026→Sep 8, 2027
Oct 14, 2026
Study completion
Sep 8, 2026→Sep 8, 2027
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Sep 8, 2026→Sep 8, 2027
    Study completion Sep 8, 2026→Sep 8, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05540782
Responsible party
Sponsor
First posted
Sep 15, 2022
Start date
Sep 8, 2022
Primary completion
Sep 8, 2027 (estimated)
Completion
Sep 8, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Kevin Liou
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion